Search results for "Angiogenesis"

showing 10 items of 552 documents

Increased Lymphangiogenesis and Lymphangiogenic Growth Factor Expression in Perivascular Adipose Tissue of Patients with Coronary Artery Disease

2019

Experimental and human autopsy studies have associated adventitial lymphangiogenesis with atherosclerosis. An analysis of perivascular lymphangiogenesis in patients with coronary artery disease is lacking. Here, we examined lymphangiogenesis and its potential regulators in perivascular adipose tissue (PVAT) surrounding the heart (C-PVAT) and compared it with PVAT of the internal mammary artery (IMA-PVAT). Forty-six patients undergoing coronary artery bypass graft surgery were included. Perioperatively collected C-PVAT and IMA-PVAT were analyzed using histology, immunohistochemistry, real time PCR, and PVAT-conditioned medium using cytokine arrays. C-PVAT exhibited increased PECAM-1 (platele…

Pathologymedicine.medical_specialtymedicine.medical_treatmentgovernment.form_of_governmentlcsh:MedicineAdipose tissue030204 cardiovascular system & hematologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrosisperivascular adipose tissuemedicineLymphatic vesselhuman030304 developmental biology0303 health sciencesbusiness.industrylcsh:Rcoronary artery disease; human; inflammation; lymphangiogenesis; perivascular adipose tissueGeneral Medicinemedicine.diseaseLymphangiogenesislymphangiogenesisVascular endothelial growth factorLymphatic EndotheliumCytokinemedicine.anatomical_structureLymphatic systemchemistryinflammationgovernmentbusinesscoronary artery diseaseJournal of Clinical Medicine
researchProduct

Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE−/−mice and angiogenesis

2015

Background and Purpose Abdominal aortic aneurysm (AAA) is a degenerative vascular disease associated with angiogenesis. Bexarotene is a retinoid X receptor (RXR) ligand with anti-angiogenic activity. Statins also exert anti-angiogenic activity and activate PPARs. Because RXR ligands form permissive heterodimers with PPARs and a single anti-angiogenic drug may not be sufficient to combat the wide array of angiogenic factors produced during AAA, we evaluated the effect of combined low doses of bexarotene and rosuvastatin in a mouse model of AAA.

PharmacologyBexaroteneAngiogenesisPharmacologyRetinoid X receptorBiologymedicine.diseaseenvironment and public healthAngiotensin IINeovascularizationAortic aneurysmRosuvastatin Calciumcardiovascular systemmedicinelipids (amino acids peptides and proteins)Rosuvastatincardiovascular diseasesmedicine.symptommedicine.drugBritish Journal of Pharmacology
researchProduct

Statins and angiogenesis in non-cardiovascular diseases.

2022

Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, …

PharmacologyCholesterolNeovascularization PathologicCardiovascular DiseasesNeoplasmsDrug DiscoveryHumansHydroxymethylglutaryl-CoA Reductase InhibitorsAngiogenesis Bone disease Brain disease Cancer Cardiovascular Diabetes Ocular disease Preeclampsia Statins VascularizationDrug discovery today
researchProduct

Anti-angiogenic therapies in prostate cancer.

2012

Prostate cancer (PCa) is the second most common type of cancer among men in Western societies. Once in the castrate-resistant metastatic setting therapeutic options are limited. The importance of angiogenesis in the progression of PCa has been widely reported providing a rationale to test anti-angiogenic compounds for PCa treatment in clinical trials (CTs). However, in spite of the promising results shown in preclinical models and some anti-tumor activity observed in CTs, to date, no angiogenic inhibitor has been approved for use in PCa. This editorial outlines the latest clinical evidence regarding anti-angiogenic therapies in PCa treatment.

PharmacologyOncologyMalePathologymedicine.medical_specialtyEvidence-Based Medicinebusiness.industryAngiogenesisClinical BiochemistryAnti angiogenicCancerProstatic NeoplasmsAngiogenesis InhibitorsEvidence-based medicineurologic and male genital diseasesmedicine.diseaseClinical trialProstate cancerClinical evidenceInternal medicineDrug DiscoverymedicineHumansbusinessExpert opinion on biological therapy
researchProduct

Ocular angiogenesis: translating preclinical indications to successful clinical development

2004

Angiogenesis-related ocular diseases such as age-related macular degeneration (AMD) or diabetic retinopathy have a high socioeconomic impact in western countries and are the leading causes of blindness. Conventional treatment modalities for AMD are of limited success. Inhibition of new vessel formation and targeting of pathological vessels seem to be the best choice in AMD. A variety of animal models mimic the relevant aspects of choroidal neovascularisation (CNV) and allow for therapy screening. Preclinical and clinical studies show that a variety of different strategies are very promising. Stategies include inhibition or blocking of vascular endothelial growth factor, a key player in angi…

PharmacologyPathologymedicine.medical_specialtygenetic structuresbusiness.industryAngiogenesisGenetic enhancementClinical BiochemistryConventional treatmentDiabetic retinopathyOcular angiogenesisMacular degenerationmedicine.diseaseBioinformaticseye diseasesVascular endothelial growth factorchemistry.chemical_compoundchemistryDrug DiscoverymedicineMolecular Medicinesense organsbusinessPathologicalExpert Opinion on Therapeutic Targets
researchProduct

Cytotoxicity of some Cameroonian spices and selected medicinal plant extracts

2011

Abstract Ethnopharmacological relevance Several medicinal plants and spices are used traditionally to treat cancers in Cameroon. Aim Methanol extracts from thirty-four spices and plants, with related ethnobotanical use were investigated for their in vitro cytotoxicity on the human pancreatic cancer cell line MiaPaCa-2, leukemia CCRF-CEM cells and their multidrug resistant (MDR) subline CEM/ADR5000, and the normal human umbilical vein endothelial cells (HUVECs). In addition the anti-angiogenic properties of the most active extracts were investigated. Material and methods The MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay was used for cyto…

PharmacologyXylopia aethiopicaEchinopsPlants MedicinalbiologyTraditional medicinePlant ExtractsAngiogenesis Inhibitorsbiology.organism_classificationAntineoplastic Agents PhytogenicPancreatic NeoplasmsMultiple drug resistanceDorsteniaCell Line TumorDrug DiscoveryCancer cellOfficinalisHumansCameroonDrug Screening Assays AntitumorSpicesCytotoxicityMedicinal plantsCells CulturedJournal of Ethnopharmacology
researchProduct

Rho-mediated activation of PI(4)P5K and lipid second messengers is necessary for promotion of angiogenesis by Semaphorin 4D

2011

Phosphatidylinositol 4-phosphate 5-kinase (PI(4)P5K) is a type I lipid kinase that generates the lipid second messenger phospholipid phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) and functions downstream of RhoA in actin organization. It is known to play an essential role in neurite remodeling, yielding a phenotype identical to that seen in cells treated with Semaphorin 4D (Sema4D), a protein that regulates proliferation, adhesion and migration in many different cell types. Plexin-B1, the receptor for Sema4D, activates RhoA in order to generate a pro-angiogenic signal in endothelial cells. Therefore, we looked in human umbilical vein endothelial cells (HUVEC) to determine if Plexin-B1 e…

Phosphatidylinositol 45-DiphosphateCancer ResearchRHOAPhysiologyAngiogenesisSemaphorin 4DClinical BiochemistrySEMA4DNeovascularization PhysiologicNerve Tissue ProteinsReceptors Cell SurfaceSemaphorinsSynaptojaninBiologySecond Messenger SystemsArticlePI(45)P2chemistry.chemical_compoundAntigens CDRhoSettore BIO/10 - BiochimicaHumansPlexin B1PhosphatidylinositolRho-associated protein kinaseCytoskeletonrho-Associated KinasesPI(4)P5KKinaseCell biologyPhosphotransferases (Alcohol Group Acceptor)AngiogenesiHEK293 CellschemistrySecond messenger systembiology.proteinCalciumrhoA GTP-Binding ProteinAngiogenesis
researchProduct

Plasmalogens in the retina: From occurrence in retinal cell membranes to potential involvement in pathophysiology of retinal diseases

2014

Plasmalogens (Pls) represent a specific subclass of glycerophospholipids characterized by the presence of a vinyl-ether bond at the sn-1 position of glycerol. Pls are quantitatively important in membranes of neuronal tissues, including the brain and the retina, where they can represent until almost two-third of ethanolamine glycerophospholipids. They are considered as reservoirs of polyunsaturated fatty acids as several studies have shown that arachidonic and docosahexaenoic acids are preferentially esterified on Pls when compared to other glycerophospholipids. Reduced levels of Pls were observed in a number of neurodegenerative disorders such as glaucoma, the second leading cause of blindn…

PlasmalogensGlycerophospholipidsBiochemistryMicrophthalmiaRetinachemistry.chemical_compoundPhospholipase A2Retinal DiseasesPhospholipase A2[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineAnimalsHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansPhospholipidschemistry.chemical_classificationRetinabiologyCell MembraneGlaucomaOptic NerveRetinalGeneral Medicinemedicine.diseaseeye diseasesBiosynthetic Pathways3. Good healthmedicine.anatomical_structureBiochemistrychemistryDocosahexaenoic acid[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansOptic nervebiology.proteinPolyunsaturated fatty acidsAngiogenesissense organs[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPolyunsaturated fatty acidBiochimie
researchProduct

Vascular endothelial growth factor-A and platelet-derived growth factor-B combination gene therapy prolongs angiogenic effects via recruitment of int…

2008

Vessel stabilization and the inhibition of side effects such as tissue edema are essential in angiogenic gene therapy. Thus, combination gene transfers stimulating both endothelial cell and pericyte proliferation have become of interest. However, there is currently little data to support combination gene transfer in large animal models. In this study, we evaluated the potential advantages of such a strategy by combining the transfer of adenoviral (Ad) vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF)-B into rabbit hindlimb skeletal muscle. AdLacZ alone or in combination with AdVEGF-A were used as controls. Contrast-enhanced ultrasound, modified Miles assa…

Platelet-derived growth factorbiologyPhysiologyAngiogenesisGrowth factormedicine.medical_treatmentVascular permeabilitygrowth factorkasvutekijägeeniterapiaVascular endothelial growth factorchemistry.chemical_compoundVascular endothelial growth factor Amedicine.anatomical_structurechemistryImmunologybiology.proteinCancer researchmedicinePericyteCardiology and Cardiovascular MedicinePlatelet-derived growth factor receptor
researchProduct

Regulatory Network Of Angiogenesis Gene Expression During Post-Pneumonectomy Compensatory Growth

2011

PneumonectomyAngiogenesismedicine.medical_treatmentGene expressionCompensatory growth (organ)medicineCancer researchBiologyA61. LUNG ENDOTHELIUM FUNCTIONS: THE BARRIER AND BEYOND
researchProduct